BACKGROUND: Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin, for which there is not yet a clearly defined function. MATERIALS AND METHODS: In this study, we determined gelsolin concentrations in blood and cerebrospinal fluid (CSF) obtained from 25 subjects using immunoblotting and a functional assay that quantifies gelsolin's ability to accelerate actin polymerization. RESULTS: The gelsolin concentration in CSF, determined by quantitative immunoblotting was 1.2-15.9 microg/ml (average 5.9 +/- 3.8 mug/ml). In samples obtained from patients diagnosed with conditions that do not alter standard CSF clinical tests [(idiopathic cephalgia, ischialgia due to discopathy, and idiopathic (Bell's) facial nerve palsy or entrapment radial neuropathy)], the average gelsolin concentration was 7.2 +/- 4.3 microg/ml. In contrast, the gelsolin concentration in samples obtained from patients diagnosed with multiple sclerosis was 2.1 +/- 0.7 microg/ml, and a similar low concentration was found in a patient recovering from a subarachnoid hemorrhage. The range of CSF gelsolin concentrations determined by the actin polymerization assay was 0.61-9.97 microg/ml (average 3.6 +/- 2.2 microg/ml). These lower values compared with those obtained from immunoblotting analysis suggest that CSF gelsolin may bind other CSF molecules leading to a reduction of its actin-binding activity. CONCLUSIONS: The results presented here show that CSF gelsolin concentration is significantly altered in certain neurological conditions, including multiple sclerosis, indicating the possible utility of CSF gelsolin levels for diagnostic purposes.
BACKGROUND:Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin, for which there is not yet a clearly defined function. MATERIALS AND METHODS: In this study, we determined gelsolin concentrations in blood and cerebrospinal fluid (CSF) obtained from 25 subjects using immunoblotting and a functional assay that quantifies gelsolin's ability to accelerate actin polymerization. RESULTS: The gelsolin concentration in CSF, determined by quantitative immunoblotting was 1.2-15.9 microg/ml (average 5.9 +/- 3.8 mug/ml). In samples obtained from patients diagnosed with conditions that do not alter standard CSF clinical tests [(idiopathic cephalgia, ischialgia due to discopathy, and idiopathic (Bell's) facial nerve palsy or entrapment radial neuropathy)], the average gelsolin concentration was 7.2 +/- 4.3 microg/ml. In contrast, the gelsolin concentration in samples obtained from patients diagnosed with multiple sclerosis was 2.1 +/- 0.7 microg/ml, and a similar low concentration was found in a patient recovering from a subarachnoid hemorrhage. The range of CSF gelsolin concentrations determined by the actin polymerization assay was 0.61-9.97 microg/ml (average 3.6 +/- 2.2 microg/ml). These lower values compared with those obtained from immunoblotting analysis suggest that CSF gelsolin may bind other CSF molecules leading to a reduction of its actin-binding activity. CONCLUSIONS: The results presented here show that CSF gelsolin concentration is significantly altered in certain neurological conditions, including multiple sclerosis, indicating the possible utility of CSF gelsolin levels for diagnostic purposes.
Authors: Nicolas Fissolo; Sabrina Haag; Katrien L de Graaf; Oliver Drews; Stefan Stevanovic; Hans Georg Rammensee; Robert Weissert Journal: Mol Cell Proteomics Date: 2009-06-16 Impact factor: 5.911
Authors: Robert Bucki; Alina Kulakowska; Fitzroy J Byfield; Malgorzata Zendzian-Piotrowska; Marcin Baranowski; Michal Marzec; Jessamine P Winer; Nicholas J Ciccarelli; Jan Górski; Wieslaw Drozdowski; Robert Bittman; Paul A Janmey Journal: Am J Physiol Cell Physiol Date: 2010-09-01 Impact factor: 4.249
Authors: Diego M Morales; R Reid Townsend; James P Malone; Carissa A Ewersmann; Elizabeth M Macy; Terrie E Inder; David D Limbrick Journal: Mol Cell Proteomics Date: 2011-12-20 Impact factor: 5.911
Authors: Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki Journal: BMC Neurol Date: 2010-11-01 Impact factor: 2.474